SCHEMBL5540583

SCHEMBL5540583

[CH2]c1ccccc1NCc1cccc(Cl)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP3A4 P08684 2/20 0.47
CYP1A2 P05177 1/20 0.47
GLA P06280 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PNMT P11086 1/20 0.44
P2RX7 Q99572 1/20 0.42
GRM2 Q14416 1/20 0.41
CXCR4 P61073 1/20 0.41
CD38 P28907 2/20 0.41
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
ALDH1A1 P00352 2/20 0.40
IDO1 P14902 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545072 0.88 L3MBTL1 (0.42) MAPTMAPK1L3MBTL1CYP3A4CYP1A2
SCHEMBL11510192 0.86 PNMT (0.50) MAPTMAPK1L3MBTL1CYP3A4CYP1A2
SCHEMBL11511927 0.82 MAPT (0.57) MAPTMAPK1L3MBTL1CYP3A4CYP1A2
SCHEMBL5545206 0.82 MAPT (0.41) MAPTMAPK1L3MBTL1CYP3A4GLA
SCHEMBL5544240 0.77 LMNA (0.47) MAPTMAPK1L3MBTL1CYP3A4CYP1A2
SCHEMBL11512000 0.76 MAPT (0.62) MAPTMAPK1L3MBTL1CYP3A4CYP2D6
SCHEMBL5543785 0.74 L3MBTL1 (0.50) MAPTL3MBTL1CYP3A4CYP1A2CYP2D6
SCHEMBL5539677 0.74 CA12 (0.44) MAPTMAPK1L3MBTL1CD38CA12
SCHEMBL5536067 0.74 CA12 (0.44) MAPTMAPK1L3MBTL1CYP1A2CYP2D6
SCHEMBL688010 0.74 MAPT (0.53) MAPTMAPK1CYP3A4CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885MAPK1 1392/4885L3MBTL1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.